Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jun 19, 2024
Product Development
Clinical Report: Zentalis hold resurfaces WEE1 safety concerns
Plus data from BioNTech, MediLink, Nurix, Aerovate and more
BioCentury | Apr 12, 2024
Finance
Public equity report: Acrivon refreshes balance sheet with $130M PIPE
Plus Eliem, Century raise private placements as they make acquisitions; Nurix’s AACR readout precedes follow-on; Skye uplists
BioCentury | May 26, 2023
Product Development
May 26 ASCO Quick Takes: BMS’s Reblozyl headed for SOC in first-line MDS
Plus: Zentalis’ azenosertib shows early promise in ovarian cancer, and updates from PDS and Elevation
BioCentury | Mar 3, 2023
Finance
March 2 Quick Takes: MorphoSys laying off staff, ending preclinical work
Plus: Flamingo teaming up with Dynacure and updates from Debiopharm, Aldeyra, Checkpoint and more
BioCentury | Jul 28, 2022
Emerging Company Profile
Vicinitas: stabilizing proteins with small molecules
a16z, Deerfield co-lead $65M series A for UC Berkeley spinout’s small molecule deubiquitination platform
BioCentury | Jun 17, 2022
Product Development
First-in-human cancer trials delivering translational innovation
New targets displaced validated mechanisms in first-in-human abstracts at ASCO 2022
BioCentury | May 27, 2022
Discovery & Translation
Shifting from binary markers to whole-genome signatures in cancer
Classifying tumors by mutational patterns across the whole genome could enable more predictive patient stratification and drug matching
BioCentury | Apr 27, 2022
Deals
Pfizer invests $25M in Zentalis, will advise on development of WEE1 program
Pharma lends Zentalis clinical expertise on a high-priority program, to which the biotech retains full ownership
BioCentury | Mar 18, 2022
Finance
Impact lands runway to clear multiple synthetic lethality milestones
Shanghai company raises $61M series D1 with eyes on global deal for WEE1, IPO
BioCentury | Mar 12, 2022
Discovery & Translation
Translational highlights to watch for at AACR
BioCentury’s roundup of translational abstracts ahead of the 2022 American Association for Cancer Research conference
Items per page:
1 - 10 of 35